Harpoon: Harpoon Therapeutics : April 3, 2024

(marketscreener.com) all assessed by both BICR and investigator - and overall survival . The Phase 3 part of REJOICE-Ovarian01 will assess the efficacy and safety of raludotatug deruxtecan at the selected dose compared to investigator's choice of chemotherapy . The dual primary endpoints of the Phase 3 part of the trial are ORR and PFS as...https://www.marketscreener.com/quote/stock/HARPOON-THERAPEUTICS-INC-54488892/news/Harpoon-Therapeutics-April-3-2024-46348884/?utm_medium=RSS&utm_content=20240403